MedCity News

AMA: PBM Market Concentration Is On the Rise

Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent

Sanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. The companies project these drugs will start reaching pivotal testing in 2029 — important because Dupixent faces patent expiration in 2031.

By Frank Vinluan

MedCity Influencers

The Real Gap in All of Us Isn’t Consent, It’s Conversion

Why more than 300,000 missing patient records reveal an engineering problem, not a policy one — and why that's good news.

By Adam Cohen

BioPharma, Pharma

FDA Looks to Bring New Scientific, Consumer Voices to Advisory Committees

The FDA is recruiting to fill vacancies on its advisory committees, informally known as adcomms. While these committees have met less frequently during the Trump administration, more meetings have been scheduled since former Commissioner Marty Makary left the agency in May.

By Frank Vinluan

Latest Video

Latest News

Health Tech

MedCity FemFwd: Opportunities in the Fertility Market

In this episode, we’re joined by Claire Love, PwC’s global health industries advisory leader. We discuss PwC’s recent report showing the opportunities in the fertility and reproductive health market.

By Marissa Plescia

Health Tech

Digital generated image of multi layered dollar sign making swirl pattern.

4 Notable Health Tech Funding Announcements in September

Health tech companies made several major funding announcements in September. Here is a list of some of the biggest funding rounds.

By Marissa Plescia

A human hand interacts with an artificial intelligence robotic hand with medical icons and a digital interface on dark background, illustrating healthcare technology AI trust

AI’s Healthcare ‘Doomsday’? It May Be Less About Autonomy Than Trust

For one ICU physician and startup CMO, the more immediate danger isn’t an autonomous system taking over medicine and leaving human decision-making behind. It’s healthcare organizations harnessing AI primarily to increase efficiency while leaving healthcare providers even more mired in complexity and regulation.

By Jenna Congdon

MedCity Influencers

AI Won’t Fix Social Care, But Could It Help Us Finally Make It Work?

AI could play a meaningful role in advancing social care. Not by replacing people, but by helping them and organizations doing this work move faster, see patterns earlier, and coordinate more effectively.

By Mark Taylor

Consumer / Employer, Health Tech

Tiny Health Secures $33M to Expand Microbiome Testing

Tiny Health's Series B round was led by B Capital, with participation from Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures.

By Marissa Plescia

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

Unite Us, Instacart Link Care Coordination and Grocery Benefits to Scale Food-as-Medicine

Unite Us and Instacart announced Tuesday that they are partnering to connect healthcare organizations’ care coordination efforts with grocery benefits, with the aim of making food-as-medicine programs easier to launch and operate at scale.

By Jenna Congdon

BioPharma, Pharma

AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug

AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment.

By Frank Vinluan

Devices & Diagnostics

MedCity Pivot Podcast: A Conversation With AliveCor’s Priya Abani

In this episode of the MedCity Pivot Podcast, CEO Priya Abani talks about the evolution of AliveCor, one of the earliest digital health companies.

By Arundhati Parmar

Opinion

The Illegal Drug Marketplace in Your Patients’ Pockets

Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation

By Fred Mills

DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data to provide insulin dosing recommendations for people with Type 2 diabetes who need both basal insulin and fast-acting injections.

By Jenna Congdon

Consumer / Employer

New Coalition Launches to Expand Direct Contracting

The Association for Direct Care launched a coalition focused on expanding direct contracting to lower healthcare costs.

By Marissa Plescia

BioPharma, Pharma

Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology.

By Frank Vinluan

MedCity Influencers

Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care

While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment.

By Wendy Insalaco and Jami Barney

BioPharma, Pharma

Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year.

By Frank Vinluan